Skip to content

Meta-Analytic Insights Into Mindfulness Approaches for Depression and Diabetes Comorbidity Care.

Kenni Wojujutari Ajele, Erhabor Sunday Idemudia

Diabetes Spectrum 2025 DOI: 10.2337/ds24-0048 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review and meta-analysis Randomized Peer reviewed
Sample size 1,336
Population People with diabetes and depressive symptoms
Topics Depression Meditation
Key findings Mindfulness-based interventions significantly reduced depressive symptoms (SMD -0.88) and improved A1C levels (SMD -0.23) in individuals with comorbid diabetes and depression.

Abstract

This study evaluated the effectiveness of mindfulness-based interventions (MBIs) in managing comorbid depression and diabetes by assessing their efficacy in reducing depressive symptoms and improving glycemic control, while addressing inconsistencies in existing research. A systematic review and meta-analysis were conducted of 17 randomized controlled trials published between 2013 and 2024 and involving 1,336 participants with diabetes and depressive symptoms. Effect sizes were calculated using Hedges' g and random-effects models, with heterogeneity assessed using I 2 statistics. MBIs significantly reduced depressive symptoms (standardized mean difference [SMD] -0.88, 95% CI -1.34 to -0.42) with high heterogeneity (I 2 = 90%) and improved A1C levels (SMD -0.23, 95% CI -0.38 to -0.08). Among intervention types, mindfulness-based stress reduction (SMD -1.02, 95% CI -1.57 to -0.48) and mindfulness-based cognitive therapy (SMD -0.92, 95% CI -1.45 to -0.39) showed strong effects. Effects varied by region, with Asian studies showing greater benefits (SMD -1.44) compared with North American studies (SMD -0.61). MBIs are effective in reducing depressive symptoms and improving glycemic control in individuals with comorbid diabetes and depression. These findings highlight the importance of culturally adapted approaches and call for further research to refine MBI applications in diabetes care.

Comparable studies

Other systematic reviews and meta-analyses on depression, most cited first.

Study Year Design Participants
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression Participants with major depression in placebo-controlled, double-blind, randomized... 2015 Systematic review and meta-analysis
Side-effects associated with ketamine use in depression: a systematic review. Patients with depression 2018 Systematic review
Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression 2020 Systematic review and meta-analysis n = 1,877
Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Patients with major depressive disorder or bipolar depression 2016 Systematic review and meta-analysis n = 588
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Patients with cancer- or illness-related anxiety and depression, major depressive... 2020 Systematic review n = 188

Citations in the library

Explore topics